Statement Of Cash Flows [Abstract]

BioInvent International - Filing #678852

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-01-01	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-01-01
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	330 304 SEK	—	330 304 SEK	—	—	42 503 SEK	42 503 SEK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories	338,000 SEK	—	—	—	—	5 342 SEK	—	—
Adjustments for depreciation and amortisation expense	16 755 SEK	—	—	—	—	14 724 SEK	—	—
Other adjustments to reconcile profit (loss)	2 950 SEK	—	—	—	—	1 789 SEK	—	—
Interest paid, classified as operating activities	638,000 SEK	—	—	—	—	650,000 SEK	—	—
Interest received, classified as operating activities	19 419 SEK	—	—	—	—	606,000 SEK	—	—
Income taxes paid (refund), classified as operating activities	90,000 SEK	—	—	—	—	– SEK	—	—
Cash flows from (used in) operating activities	341 691 SEK	—	—	—	—	41 227 SEK	—	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	13 304 SEK	—	—	—	—	12 377 SEK	—	—
Cash flows from (used in) investing activities	59 681 SEK	—	—	—	—	628 848 SEK	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	30 959 SEK	—	—	—	—	279 849 SEK	—	—
Payments of lease liabilities, classified as financing activities	7 820 SEK	—	—	—	—	6 362 SEK	—	—
Cash flows from (used in) financing activities	23 139 SEK	—	—	—	—	273 487 SEK	—	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	258 871 SEK	—	—	—	—	396 588 SEK	—	—
Cash and cash equivalents	—	259 548 SEK	—	515 047 SEK	515 047 SEK	—	—	910 755 SEK